Log in

Relevant bibliographies by topics / Arformoterol / Journal articles

To see the other types of publications on this topic, follow the link: Arformoterol.

Journal articles on the topic 'Arformoterol'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Arformoterol.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

King, Paul T. "Pharmacotherapy of Chronic Obstructive Pulmonary Disease: Focus on Arformoterol Tartrate." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S2584. http://dx.doi.org/10.4137/cmt.s2584.

Full text

Abstract:

Arformoterol tartrate is a newly developed long-acting ssβ2-agonist with both acute and prolonged bronchodilator effects. It is formed of 2 isomers (R,R/R,R) which distinguishes it from the more commonly used racemic formoterol (R,R/S,S). The active isomer is the (R,R) and in vitro arformoterol may have more potent anti-inflammatory effects than formoterol. It can only be given by a nebulizer. There have been 5 randomized, blinded trials which have assessed the use of arformoterol in chronic obstructive pulmonary disease (COPD). Arformoterol has been demonstrated to improve lung function and s

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Arformoterol." Drugs in R & D 5, no. 1 (2004): 25–27. http://dx.doi.org/10.2165/00126839-200405010-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hazra, Moumita. "A pharmacoepidemiological study of prescription patterns of β2 sympathomimetic bronchodilators in exacerbation of non-severe asthma in tertiary care hospitals, not needing hospitalization". International Journal of Basic & Clinical Pharmacology 8, № 12 (2019): 2674. http://dx.doi.org/10.18203/2319-2003.ijbcp20195276.

Full text

Abstract:

Background: Arformoterol, the (R, R) enantiomer of the racemic (R, R / S, S) diastereomer, formoterol, is a short and long acting β2 agonist bronchodilator. Levosalbutamol, the (R, R) enantiomer of racemic diastereomer (R, R / S, S) salbutamol, has a greater affinity for the β2 receptor. Occupation of β2 receptors by agonists result in the activation of the Gs-adenylyl cyclase-cAMP-PKA pathway, followed by phosphorylative events leading to bronchial smooth muscle relaxation. The aim of this pharmacoepidemiological study was to analyse the prescription patterns, and prescription content analysi

APA, Harvard, Vancouver, ISO, and other styles

4

Cada, Dennis J., Terri Levien, and Danial E. Baker. "Arformoterol Tartrate." Hospital Pharmacy 42, no. 5 (2007): 447–54. http://dx.doi.org/10.1310/hpj4205-447.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Revill, P., N. Serradell, J. Bolós, and M. Bayés. "Arformoterol Tartrate." Drugs of the Future 31, no. 11 (2006): 944. http://dx.doi.org/10.1358/dof.2006.031.11.1047743.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Arformoterol comparable to salmeterol for COPD." Inpharma Weekly &NA;, no. 1558 (2006): 6. http://dx.doi.org/10.2165/00128413-200615580-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cazzola, Mario, Nicola A. Hanania, and Maria G. Matera. "Arformoterol tartrate in the treatment of COPD." Expert Review of Respiratory Medicine 4, no. 2 (2010): 155–62. http://dx.doi.org/10.1586/ers.10.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bhutnar, Arun, Anita Desai, Sachin Khapare, Sonali Vartak, Ajay Pangavhane, and Allwyn Andrandes. "Identification and Structural Characterization of Secondary Degradant of Arformoterol Impurity in LDPE Respules of Arformoterol Tartrate Inhalation Solution." American Journal of Analytical Chemistry 09, no. 05 (2018): 286–301. http://dx.doi.org/10.4236/ajac.2018.95022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

King, Paul. "Role of arformoterol in the management of COPD." International Journal of Chronic Obstructive Pulmonary Disease Volume 3 (September 2008): 385–91. http://dx.doi.org/10.2147/copd.s753.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Jeong, Jin-Hyuk, Jaewoon Son, Ji-Hyeon Kwon, Chang-Soo Han, and Chun-Woong Park. "Impact of Different Hydrate Forms of Magnesium Stearate as a Flow Control Agent on the Physical Stability and Inhalation Efficiency of Carrier-Based Formulations." Pharmaceutics 17, no. 6 (2025): 711. https://doi.org/10.3390/pharmaceutics17060711.

Full text

Abstract:

Objectives: This study aimed to evaluate the impact of the different hydration states of magnesium stearate (Mg.st) anhydrate (AH), monohydrate (MH), and dihydrate (DH) on the aerodynamic performance and stability of carrier-based dry powder inhalation (DPI) formulations using arformoterol and budesonide as model drugs. Methods: DPI formulations were prepared using Inhalac 251 lactose and Mg.st in various hydrated forms. The physicochemical properties of Mg.st were characterized using powder X-ray diffraction, differential scanning calorimetry, Fourier-transform infrared spectroscopy, Karl Fis

APA, Harvard, Vancouver, ISO, and other styles

11

Terasaki, Jordan, Shawn PE Nishi, Bill T. Ameredes, and Gulshan Sharma. "Arformoterol: rationale for use in chronic obstructive pulmonary disease." Clinical Investigation 4, no. 5 (2014): 429–39. http://dx.doi.org/10.4155/cli.14.32.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

*Krishnaphanisri, Ponnekanti, Anusha Addanki, Raj Kamal B., Bhavani Dasari Durga, Reddy Gargula Sumana, and Reddy Karnati Shiva. "A REVIEW-ON METHOD DEVELOPMENT & METHOD VALIDATION BY RP-HPLC FOR ESTIMATION OF ARFORMOTEROL." World Journal of Pharmaceutical Science and Research 4, no. 2 (2025): 1062–70. https://doi.org/10.5281/zenodo.15364947.

Full text

Abstract:

Arformoterol is a long-acting β<sub>2</sub> adrenoreceptor agonist (LABA) and it is the active (<em>R</em>,<em> R</em>)-(−)enantiomer of formoterol. It was approved for medical use in the United States in October 2006. It is available as a generic medication. Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). The purpose of analytical method development is to establish the identity, purity, physical characteristics, and potency of drugs, including the drug’s bioavailability and stability.

APA, Harvard, Vancouver, ISO, and other styles

13

Hanania, Nicola A., James F. Donohue, Harold Nelson, et al. "The Safety and Efficacy of Arformoterol and Formoterol in COPD." COPD: Journal of Chronic Obstructive Pulmonary Disease 7, no. 1 (2010): 17–31. http://dx.doi.org/10.3109/15412550903499498.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Bonasia, Phil, Carrie Cook, Yufei Cheng, and Shaowei Ong. "Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs." Current Medical Research and Opinion 23, no. 10 (2007): 2477–83. http://dx.doi.org/10.1185/030079907x233106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Miles, Matthew C., James F. Donohue, and Jill A. Ohar. "Nebulized arformoterol: what is its place in the management of COPD?" Therapeutic Advances in Respiratory Disease 7, no. 2 (2012): 81–86. http://dx.doi.org/10.1177/1753465812465784.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Baumgartner, Rudolf A., John P. Hanrahan та Kenneth Sciarappa. "NEBULIZED ARFORMOTEROL, A LONG-ACTING β2 -ADRENERGIC BRONCHODILATOR, IN PATIENTS WITH COPD." Critical Care Medicine 34 (грудень 2006): A95. http://dx.doi.org/10.1097/00003246-200612002-00329.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Hanania, Nicola, James Donohue, Harold Nelson, et al. "LONG-TERM SAFETY AND EFFICACY OF NEBULIZED ARFORMOTEROL IN SUBJECTS WITH COPD." Chest 134, no. 4 (2008): 106P. http://dx.doi.org/10.1378/chest.134.4_meetingabstracts.p106001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Celli, Bartolome, Maryam Navaie, Vaidyanathan Ganapathy, Zhun Xu, Soojin Cho-Reyes, and Todd Gilmer. "Medication Management Patterns Among Medicare Beneficiaries With COPD Initiating Nebulized Arformoterol Treatment." Chest 152, no. 4 (2017): A775. http://dx.doi.org/10.1016/j.chest.2017.08.806.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Loh, Chee H., James F. Donohue, and Jill A. Ohar. "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease." Expert Opinion on Drug Safety 14, no. 3 (2015): 463–72. http://dx.doi.org/10.1517/14740338.2015.998196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hanrahan, John P., Donna Grogan, Joel Morganroth, Hailong Cheng, and Rudolf Baumgartner. "THE EFFECT OF TWICE-DAILY NEBULIZED ARFORMOTEROL ON QTC IN SUBJECTS WITH COPD." Chest 132, no. 4 (2007): 532C. http://dx.doi.org/10.1378/chest.132.4_meetingabstracts.532c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bauer, Andrea, Paul McGlynn, Li Li Bovet, P. Mims, Lisa Curry, and John Hanrahan. "THE INFLUENCE OF BREATHING PATTERN DURING NEBULIZATION ON THE EMITTED DOSE OF ARFORMOTEROL." Chest 132, no. 4 (2007): 616B. http://dx.doi.org/10.1378/chest.132.4_meetingabstracts.616b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Panettieri, Reynold A., Neil MacIntyre, Michael Sims та ін. "Comparison of the efficacy and safety of arformoterol 15 μg twice daily and arformoterol 30 μg once daily in COPD: A single-dose, multicenter, randomized, modified-blind, two-way crossover study". Clinical Therapeutics 31, № 8 (2009): 1716–23. http://dx.doi.org/10.1016/j.clinthera.2009.08.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ganapathy, Vaidyanathan, and Michael D. Stensland. "Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol." International Journal of Chronic Obstructive Pulmonary Disease Volume 12 (June 2017): 1793–801. http://dx.doi.org/10.2147/copd.s134145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Madaan, A. "Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease." Drugs of Today 45, no. 1 (2009): 3. http://dx.doi.org/10.1358/dot.2009.45.1.1313983.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Hanrahan, John P., Nicola A. Hanania, William J. Calhoun, Steven A. Sahn, Kenneth Sciarappa, and Rudolf A. Baumgartner. "Effect of Nebulized Arformoterol on Airway Function in COPD: Results from Two Randomized Trials." COPD: Journal of Chronic Obstructive Pulmonary Disease 5, no. 1 (2008): 25–34. http://dx.doi.org/10.1080/15412550701816187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Hanrahan, J. P., W. B. Smith, K. Sciarappa, W. K. McVicar, and R. A. Baumgartner. "EFFICACY AND SAFETY OF NEBULIZED ARFORMOTEROL IN COPD: A PROSPECTIVE, PHASE III CLINICAL TRIAL." Chest 130, no. 4 (2006): 181S. http://dx.doi.org/10.1378/chest.130.4_meetingabstracts.181s-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Stensland, Mike, Vamsi Bollu, and James Donohue. "Hospital Readmissions Among Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Arformoterol or Tiotropium." Chest 148, no. 4 (2015): 714A. http://dx.doi.org/10.1378/chest.2279106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Tashkin, D. P., J. F. Donohue, D. A. Mahler, et al. "Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD." Respiratory Medicine 103, no. 4 (2009): 516–24. http://dx.doi.org/10.1016/j.rmed.2008.12.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Tashkin, Donald, James Donohue, Donald Mahler, et al. "EFFECT OF ARFORMOTEROL TWICE DAILY, TIOTROPIUM ONCE DAILY, AND THEIR COMBINATION IN SUBJECTS WITH COPD." Chest 134, no. 4 (2008): 104P. http://dx.doi.org/10.1378/chest.134.4_meetingabstracts.p104003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Hinkle, J., J. Hinson, E. Kerwin, et al. "A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma." Pediatric Pulmonology 46, no. 8 (2011): 761–69. http://dx.doi.org/10.1002/ppul.21446.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Celli, Bartolome R., Maryam Navaie, Zhun Xu, Soojin Cho-Reyes, Carole Dembek, and Todd P. Gilmer. "Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment." International Journal of Chronic Obstructive Pulmonary Disease Volume 14 (May 2019): 1019–31. http://dx.doi.org/10.2147/copd.s199251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Gilmer, Todd P., Bartolome R. Celli, Zhun Xu, Soojin Cho-Reyes, Carole Dembek, and Maryam Navaie. "Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease*." COPD: Journal of Chronic Obstructive Pulmonary Disease 16, no. 2 (2019): 140–51. http://dx.doi.org/10.1080/15412555.2019.1618256.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Stensland, Mike, Vamsi Bollu, and James Donohue. "Hospital Readmissions Among Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Arformoterol or Fluticasone/Salmeterol." Chest 148, no. 4 (2015): 716A. http://dx.doi.org/10.1378/chest.2278614.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Bollu, V., L. M. Nelson, V. S. Williams, M. D. Stensland, and D. E. Stull. "Symptom Response Profiles For Patients With Chronic Obstructive Pulmonary Disease Initiating Nebulized Arformoterol Tartrate Or Placebo." Value in Health 17, no. 3 (2014): A170. http://dx.doi.org/10.1016/j.jval.2014.03.995.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Donohue, James F., Nicola A. Hanania, Barry Make, et al. "One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD." Chest 146, no. 6 (2014): 1531–42. http://dx.doi.org/10.1378/chest.14-0117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Hanania, Nicola, James Donohue, and Barry Make. "A Large Simple Safety Study of Nebulized Arformoterol Tartrate: Incidence and Risk of Protocol-Defined COPD Exacerbations." Chest 144, no. 4 (2013): 735A. http://dx.doi.org/10.1378/chest.1704476.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Sepracor has launched arformoterol [Brovana] inhalation solution in the US for bronchoconstriction in chronic obstructive pulmonary disorder." Inpharma Weekly &NA;, no. 1584 (2007): 27. http://dx.doi.org/10.2165/00128413-200715840-00083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Sharma, Sanjay, Ayca Ozol-Godfrey, Thomas Goodin, Barry Price, and Shahin Sanjar. "AN ASSESSMENT OF TIME TO ONSET OF BRONCHODILATION FOLLOWING TREATMENT WITH NEBULIZED ARFORMOTEROL IN PATIENTS WITH COPD." Chest 156, no. 4 (2019): A1622—A1623. http://dx.doi.org/10.1016/j.chest.2019.08.1425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Bollu, V., R. Carlton, and R. S. Clark. "Health Care Resource Utilization And Rehospitalization Costs Of Nebulized Arformoterol For The Treatment Of Chronic Obstructive Pulmonary Disease." Value in Health 17, no. 3 (2014): A173. http://dx.doi.org/10.1016/j.jval.2014.03.1007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Bollu, V., Y. J. Chen, and C. Makin. "Treatment Persistence Comparison Between Nebulized Formulations Of Arformoterol And Formoterol In The Treatment Of Chronic Obstructive Pulmonary Disease." Value in Health 17, no. 3 (2014): A177. http://dx.doi.org/10.1016/j.jval.2014.03.1035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Kharidia, Jahnavi, Charles Fogarty, Craig LaForce, et al. "AN OPEN LABEL STUDY OF ARFORMOTEROL INHALATION SOLUTION AND RACEMIC FORMOTEROL DRY POWDER INHALER IN SUBJECTS WITH COPD." Chest 132, no. 4 (2007): 533B. http://dx.doi.org/10.1378/chest.132.4_meetingabstracts.533b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Donohue, J. F., N. A. Hanania, K. A. Sciarappa, et al. "Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance." Therapeutic Advances in Respiratory Disease 2, no. 2 (2008): 37–48. http://dx.doi.org/10.1177/1753465808089455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Das, SibesK, ArunK Bandyopadhyay, Somnath Bhattacharya, Indranil Biswas, and TapanD Bairagya. "A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma." Indian Journal of Pharmacology 43, no. 4 (2011): 463. http://dx.doi.org/10.4103/0253-7613.83123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Donohue, James F., Vaidyanathan Ganapathy, Vamsi Bollu, Michael D. Stensland, and Lauren M. Nelson. "Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year." Clinical Therapeutics 39, no. 1 (2017): 66–74. http://dx.doi.org/10.1016/j.clinthera.2016.11.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Baumgartner, Rudolf A., Nicola A. Hanania, William J. Calhoun, Steven A. Sahn, Kenneth Sciarappa, and John P. Hanrahan. "Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial." Clinical Therapeutics 29, no. 2 (2007): 261–78. http://dx.doi.org/10.1016/j.clinthera.2007.02.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Sun, Chenglong, Jiuming He, Hongbo Wu, et al. "A rapid and sensitive UPLC–MS/MS method for quantitative determination of arformoterol in rat plasma, lung and trachea tissues." Chinese Chemical Letters 29, no. 8 (2018): 1284–86. http://dx.doi.org/10.1016/j.cclet.2018.01.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Donohue, James F., Vamsi K. Bollu, Donald E. Stull, et al. "Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial." International Journal of Chronic Obstructive Pulmonary Disease Volume 13 (February 2018): 499–508. http://dx.doi.org/10.2147/copd.s141729.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Nabi, Nusrat, Rishika Agarwal, Himika Mukhopadhyay, et al. "A PHARMACOLOGICAL COMPARATIVE STUDY OF ARFORMOTEROL AND SALBUTAMOL NEBULIZATION IN THE MANAGEMENT OF PATIENTS SUFFERING FROM ACUTE NON-SEVERE BRONCHIAL ASTHMA." Journal of Evolution of Medical and Dental Sciences 6, no. 03 (2017): 215–18. http://dx.doi.org/10.14260/jemds/2017/50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Sciurba, Frank, Claudia Cote, Kenneth Sciarappa, Elizabeth Goodwin, Lisa Curry, and John Hanrahan. "ASSESSMENT OF PATIENT SYMPTOM AND FUNCTIONING OUTCOMES AMONG COPD SUBJECTS TREATED WITH ARFORMOTEROL OR RACEMIC FORMOTEROL: A 6-MONTH CLINICAL TRIAL." Chest 134, no. 4 (2008): 16P. http://dx.doi.org/10.1378/chest.134.4_meetingabstracts.p16002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Navaie, Maryam, Bartolome R. Celli, Zhun Xu, Soojin Cho-Reyes, Carole Dembek, and Todd P. Gilmer. "Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event." Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 6, no. 4 (2019): 297–307. http://dx.doi.org/10.15326/jcopdf.6.4.2019.0127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!